![Scantox enters transformational acquisition of QPS Neuropharmacology](https://impilo.se/wp-content/uploads/2024/03/impilo-news-4-340x260.png)
Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the eye, in certain European countries from Novartis. The deal encompasses commercial and distribution rights and intellectual property for the four products in the territories.
Read moreNews
![](https://impilo.se/wp-content/uploads/2024/09/MiniGo_600x337_130324-315x300.png)
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.
![](https://impilo.se/wp-content/uploads/2024/04/ana-francisconi-1436548-unsplash-315x500.jpg)
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
![](https://impilo.se/wp-content/uploads/2024/02/cris-trung-3wK7RLRAAkA-unsplash_aviapharma_landingpage-qj7uiwo7cyjal8ag8kydvsn338wmo96z2gi19upjgw.jpeg-315x300.webp)
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.